Movement Alert｜AKESO Falls 3.11% in Regular Trading, Profit-Taking After Two-Day Rally Amid Sector Pullback

Market Focus07-24

On July 24, AKESO fell 3.11% in regular trading, trading at 99.55 HKD/share, with turnover of 452 million HKD.

The decline comes after two consecutive sessions of strong gains, with the stock having risen approximately 7% on July 22 and over 4% on July 23, triggering profit-taking pressure. The broader biotechnology sector also traded weak, with Remegen down 3.84%, 3SBio down 2.11%, SKB Bio down 0.96%, and Innovent Bio down 0.16%, creating synchronized downward pressure. Only BeiGene bucked the trend, rising 3.41%.

On the fundamental side, overseas partner Summit Therapeutics recently updated overall survival data from the global Phase III HARMONi study of ivonescimab, showing OS hazard ratio improved to 0.76 for Western patients, confirming cross-ethnic efficacy consistency. The data has been submitted to the FDA to support BLA review, and the mid-to-long-term global registration value remains unchanged.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160418569?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 13:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160418569","market":"us","top_or_hot":-1,"title":"Movement Alert｜AKESO Falls 3.11% in Regular Trading, Profit-Taking After Two-Day Rally Amid Sector Pullback","media":"Market Focus","content":"<p><p>On July 24, AKESO fell 3.11% in regular trading, trading at 99.55 HKD/share, with turnover of 452 million HKD.</p><p>The decline comes after two consecutive sessions of strong gains, with the stock having risen approximately 7% on July 22 and over 4% on July 23, triggering profit-taking pressure. The broader biotechnology sector also traded weak, with Remegen down 3.84%, 3SBio down 2.11%, SKB Bio down 0.96%, and Innovent Bio down 0.16%, creating synchronized downward pressure. Only BeiGene bucked the trend, rising 3.41%.</p><p>On the fundamental side, overseas partner Summit Therapeutics recently updated overall survival data from the global Phase III HARMONi study of ivonescimab, showing OS hazard ratio improved to 0.76 for Western patients, confirming cross-ethnic efficacy consistency. The data has been submitted to the FDA to support BLA review, and the mid-to-long-term global registration value remains unchanged.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AKESO Falls 3.11% in Regular Trading, Profit-Taking After Two-Day Rally Amid Sector Pullback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AKESO Falls 3.11% in Regular Trading, Profit-Taking After Two-Day Rally Amid Sector Pullback\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-24 13:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 24, AKESO fell 3.11% in regular trading, trading at 99.55 HKD/share, with turnover of 452 million HKD.</p><p>The decline comes after two consecutive sessions of strong gains, with the stock having risen approximately 7% on July 22 and over 4% on July 23, triggering profit-taking pressure. The broader biotechnology sector also traded weak, with Remegen down 3.84%, 3SBio down 2.11%, SKB Bio down 0.96%, and Innovent Bio down 0.16%, creating synchronized downward pressure. Only BeiGene bucked the trend, rising 3.41%.</p><p>On the fundamental side, overseas partner Summit Therapeutics recently updated overall survival data from the global Phase III HARMONi study of ivonescimab, showing OS hazard ratio improved to 0.76 for Western patients, confirming cross-ethnic efficacy consistency. The data has been submitted to the FDA to support BLA review, and the mid-to-long-term global registration value remains unchanged.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1160418569","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160418569","pubTimestamp":1784870555,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 24, AKESO fell 3.11% in regular trading, trading at 99.55 HKD/share, with turnover of 452 million HKD.The decline comes after two consecutive sessions of strong gains, with the stock having...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"走势警报|AKESO 在常规交易中下跌 3.11%，在板块回调中上涨两天后获利了结","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On July 24, AKESO fell 3.11% in regular trading, trading at 99.55 HKD/share, with turnover of 452 million HKD.The decline comes after two consecutive sessions of strong gains, with the stock having risen approximately 7% on July 22 and over 4% on July 23, triggering profit-taking pressure. The broader biotechnology sector also traded weak, with Remegen down 3.84%, 3SBio down 2.11%, SKB Bio down 0.96%, and Innovent Bio down 0.16%, creating synchronized downward pressure. Only BeiGene bucked the trend, rising 3.41%.On the fundamental side, overseas partner Summit Therapeutics recently updated overall survival data from the global Phase III HARMONi study of ivonescimab, showing OS hazard ratio improved to 0.76 for Western patients, confirming cross-ethnic efficacy consistency. The data has been submitted to the FDA to support BLA review, and the mid-to-long-term global registration value remains unchanged.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160418569","isCrawlerRequest":true}